Biosimilar Position Statement


Our biosimilar position statement henceforth is as follows:

 

If an originator biologic product is on the joint formulary, the new biosimilar product will also be included on the formulary in accordance with its UK license when it becomes commercially available.

Last updated by: Annie Bolton on 06-07-2016 13:31